Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors

Plain-language summary

This study examines the ten-year persistence of biologic drugs in patients with psoriasis, along with the genetic and cardiometabolic factors that influence it. It included adults aged 18 and older with moderate-to-severe psoriasis who started biologic treatment between 2010 and 2020. It was conducted as a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Juan Ruano Ruiz

Intervention

Biologic therapy for psoriasis

Start date

1/1/2012

Estimated completion

6/1/2024

Countries

Spain

Related genes

Locations

• Córdoba, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adults (≥18 years) diagnosed with moderate-to-severe cutaneous psoriasis.
* Initiation of treatment with a biologic agent between 2010 and 2020.
* Minimum follow-up of 12 months or until drug discontinuation.
* Availability of clinical and treatment data at baseline.
* Availability of at least one blood sample for biomarker/genetic analysis.
* Informed consent obtained for biobanking and genetic analyses.

Exclusion Criteria:

* Diagnosis of other chronic inflammatory skin diseases (e.g., atopic dermatitis, lupus).
* Concomitant participation in interventional clinical trials at baseline.
* Patients with incomplete treatment history or missing survival data.
* Systemic immunosuppressive therapy (e.g., cyclosporine, methotrexate) without biologics during the study period.